Leuven, BELGIUM – June 4, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on June 3, 2025, from Atlas Special Opportunities II, LLC indicating that as of May 30, 2025, it held 244,798 shares of the then outstanding 6,156,035 shares, and therefore crossed under the threshold (5%) by virtue of the selling of voting securities. See pdf file for annex.
About Oxurion
Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.
No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
________
- Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.
This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yWpwZcptk5iYy26cZZtnaJVrameTmWOWZ2KexmZpZseVm5uVnWlhaJbLZnJjlWpq
- Check this key: https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
- Information on the total number of voting rights and shares making up the share capital
Full and original press release in PDF: https://www.actusnews.com/news/92054-oxur-transparency-notification-en-20250604.pdf
Leuven, BELGIUM – June 4, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on June 3, 2025, from Atlas Special Opportunities II, LLC indicating that as of May 30, 2025, it held 244,798 shares of the then outstanding 6,156,035 shares, and therefore crossed under the threshold (5%) by virtue of the selling of voting securities. See pdf file for annex.
About Oxurion
Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.
No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
________
- Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.
This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yWpwZcptk5iYy26cZZtnaJVrameTmWOWZ2KexmZpZseVm5uVnWlhaJbLZnJjlWpq
- Check this key: https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
- Information on the total number of voting rights and shares making up the share capital
Full and original press release in PDF: https://www.actusnews.com/news/92054-oxur-transparency-notification-en-20250604.pdf
www.actusnews.com, it's free